| Literature DB >> 31322437 |
Ulrike Luderer1, Brenda Eskenazi2, Russ Hauser3, Kenneth S Korach4, Cliona M McHale2, Francisco Moran5, Linda Rieswijk2,6, Gina Solomon7, Osamu Udagawa8, Luoping Zhang2, Marya Zlatnik9, Lauren Zeise5, Martyn T Smith2.
Abstract
BACKGROUND: Identification of female reproductive toxicants is currently based largely on integrated epidemiological and in vivo toxicology data and, to a lesser degree, on mechanistic data. A uniform approach to systematically search, organize, integrate, and evaluate mechanistic evidence of female reproductive toxicity from various data types is lacking.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31322437 PMCID: PMC6791466 DOI: 10.1289/EHP4971
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Female-specific apical end points of reproductive toxicity measured in guideline studies of the U.S. EPA and/or OECD.
| Reproductive process or end point | Assay |
|---|---|
| Estrous cycling | Vaginal cytology |
| Reproductive organ size | Weights of ovaries, uterus (with oviducts and cervix), pituitary |
| Reproductive organ structure | Macroscopic and histopathological examination of ovaries, uterus, oviducts, cervix, vagina, pituitary, mammary gland. Enumeration of ovarian primordial follicles |
| Development | Puberty (vaginal opening, first vaginal estrus in rodents), anogenital distance, structure of external genitalia |
| Pregnancy | Pregnancy rate, number of implantation sites, preimplantation mortality, birth rate, number and sex of live and dead pups at birth, fetal/neonatal body weights |
Note: EPA, Environmental Protection Agency; OECD, Organization for Economic Cooperation and Development.
Figure 1.The ten key characteristics of female reproductive toxicants. Example toxicants and associated mechanisms are provided in Table 2. Image: © Linda Rieswijk.
Key characteristics of female reproductive toxicants.
| Characteristic | Example toxicants | Known mechanistic pathway associated with female adverse reproductive outcomes |
|---|---|---|
| 1. Alters hormone receptor signaling; alters reproductive hormone production, secretion, or metabolism | Methoxychlor | ER |
| Atrazine | Inhibition of LH and PRL secretion mediated by alteration of hypothalamic GnRH and dopamine signaling ( | |
| 2. Chemical or metabolite is genotoxic | Benzo[ | Metabolism to DNA-damaging diol epoxide, radical cation, and quinone metabolites ( |
| Cyclophosphamide | Phosphoramide mustard metabolite causes dsDNA breaks in oocytes of primordial follicles in cultured neonatal ovaries ( | |
| 3. Induces epigenetic alterations | Bisphenol A | Altered DNA methylation of maternal imprinted genes in oocytes, embryos, placenta ( |
| Diethylstilbestrol | Altered DNA methylation and histone acetylation and methylation in developing uterus ( | |
| 4. Causes mitochondrial dysfunction | Methoxychlor | Inhibition of OXPHOS, increased ROS causing follicle apoptosis ( |
| Rotenone | Inhibition of complex I of electron transport chain with decreased ATP production and increased ROS, resulting in failure of oocyte meiosis ( | |
| 5. Induces oxidative stress | Chromium VI | Increased ovarian and placental hydrogen peroxide, lipid peroxidation, decreased antioxidant gene expression with |
| Methoxychlor | Increased ovarian hydrogen peroxide, oxidative protein and DNA damage; atresia of cultured antral follicles ( | |
| 6. Alters immune function | NSAIDs | Inhibition of follicular prostaglandin synthesis resulting in inhibition of ovulation ( |
| TCDD | Inhibition of natural killer cells and increased neutrophil activity at sites of ectopic endometrium in mouse model of endometriosis ( | |
| 7. Alters cell signal transduction | TCDD | Disruption of EGFR, MAPK, PTK, c-Src signaling in monkey endocervical cells ( |
| Cyclophosphamide | Alters AKT signaling in oocytes of small follicles ( | |
| 8. Alters direct cell–cell interactions | Benzo[ | Decreased sperm–egg binding and fusion ( |
| DMBA | Decreased ovarian gap junction mRNA and protein levels ( | |
| 9. Alters survival, proliferation, cell death, or metabolic pathways | Dibutyl phthalate | Cell cycle arrest in antral follicles ( |
| Benzo[ | Apoptosis of germ cells in | |
| DHEA | Inhibition of oocyte pentose phosphate pathway ( | |
| 10. Alters microtubules and associated structures | Colchicine, colcemid, carbendazim | Meiotic spindle disruption, aneuploidy (reviewed by |
| Cigarette smoke | Oviductal cilia dysfunction ( |
Note: AKT: protein kinase B; c-Src: proto-oncogene tyrosine-protein kinase Src; DHEA: dehydroepiandrosterone; DMBA: 7,12-dimethyl-benz[a]anthracene; dsDNA, double-stranded DNA; EGFR: epidermal growth factor receptor; ER: estrogen receptor; GnRH: gonadotropin-releasing hormone; HPTE: 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane; LH: luteinizing hormone; MAPK: mitogen-activated protein kinase; NSAIDs: nonsteroidal anti-inflammatory drugs; OXPHOS: oxidative phosphorylation; PTK: protein tyrosine kinase; PRL: prolactin; ROS: reactive oxygen species; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin.